The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Tetracyclines Convert the Osteoclastic-Differentiation Pathway of Progenitor Cells To Produce Dendritic Cell-like Cells
Abstract
Tetracyclines, such as doxycycline and minocycline, are used to suppress the growth of bacteria in patients with inflammatory diseases. Tetracyclines have been shown to prevent bone loss, but the mechanism involved is unknown. Osteoclasts and dendritic cells (DCs) are derived from common progenitors, such as bone marrow-derived macrophages (BMMs). In this article, we show that tetracyclines convert the differentiation pathway, resulting in DC-like cells not osteoclasts. Doxycycline and minocycline inhibited the receptor activator of NF-κB ligand (RANKL)-induced osteoclastogenesis of BMMs, but they had no effects on cell growth and phagocytic activity. They influenced neither the proliferation nor the differentiation of bone-forming osteoblasts. Surprisingly, doxycycline and minocycline induced the expression of DC markers, CD11c and CD86, in BMMs in the presence of RANKL. STAT5 is involved in DC differentiation induced by GM-CSF. Midostaurin, a STAT5-signaling inhibitor, and an anti–GM-CSF–neutralizing Ab suppressed the differentiation induced by GM-CSF but not by tetracyclines. In vivo, the injection of tetracyclines into RANKL-injected mice and RANKL-transgenic mice suppressed RANKL-induced osteoclastogenesis and promoted the concomitant appearance of CD11c+ cells. These results suggested that tetracyclines prevent bone loss induced by local inflammation, including rheumatoid arthritis and periodontitis, through osteoclast–DC-like cell conversion.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Additionally, MINO inhibits the proliferation of bone marrow-derived macrophages (BMMs) (Kinugawa et al., 2012).”
From Minocycline-loaded PLGA electrospun membrane prevents alveolar bone loss in experimental peridontitis (2020) · cites this paper as Kinugawa et al., 2012
In the citing paper
“Several studies have demonstrated that a therapeutic level of MINO promotes the proliferation and differentiation of human bone marrow osteoblastic cells (Gomes & Fernandes, 2007), mouse bone marrow cells (Nagasawa et al., 2011), and osteoblasts cells (Kinugawa et al., 2012).”
From Minocycline-loaded PLGA electrospun membrane prevents alveolar bone loss in experimental peridontitis (2020) · cites this paper as Kinugawa et al., 2012
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Takayanagi, H., Kim, S., Koga, T., Nishina, H., Isshiki, M., Yoshida, H., Saiura, A., Isobe, M., Yokochi, T., Inoue, J.-I., et al. (2002) · Developmental Cell · doi:10.1016/s1534-5807(02)00369-6 · Cited by 2,701
Osteoimmunology: shared mechanisms and crosstalk between the immune and bone systems
Takayanagi, H. (2007) · Nature Reviews Immunology · doi:10.1038/nri2062 · Cited by 1,878
Yoshida, H., Hayashi, S.-I., Kunisada, T., Ogawa, M., Nishikawa, S., Okamura, H., Sudo, T., Shultz, L. D., & Nishikawa, S.-I. (1990) · Nature · doi:10.1038/345442a0 · Cited by 1,789
Yasuda, H., Shima, N., Nakagawa, N., Mochizuki, S.-I., Yano, K., Fujise, N., Sato, Y., Goto, M., Yamaguchi, K., Kuriyama, M., et al. (1998) · Endocrinology · doi:10.1210/endo.139.3.5837 · Cited by 1,201
Self-citation
Research works printed but not linked: 45
- Teitelbaum, 2003, Genetic regulation of osteoclast development and function, Nat. Rev. Genet., 4, 638, 10.1038/nrg1122 · DOI · Paper page
- Chambers, 2010, The birth of the osteoclast, Ann. N. Y. Acad. Sci., 1192, 19, 10.1111/j.1749-6632.2009.05224.x · DOI
- Roodman, 2006, Regulation of osteoclast differentiation, Ann. N. Y. Acad. Sci., 1068, 100, 10.1196/annals.1346.013 · DOI · Paper page
- Yasuda, 1998, Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL, Proc. Natl. Acad. Sci. USA, 95, 3597, 10.1073/pnas.95.7.3597 · DOI · Paper page
- Kong, 1999, OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis, Nature, 397, 315, 10.1038/16852 · DOI · Paper page
- Suda, 1999, Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families, Endocr. Rev., 20, 345, 10.1210/edrv.20.3.0367 · DOI · Paper page
- Simonet, 1997, Osteoprotegerin: a novel secreted protein involved in the regulation of bone density, Cell, 89, 309, 10.1016/S0092-8674(00)80209-3 · DOI · Paper page
- Li, 2003, p38 Mitogen-activated protein kinase is crucially involved in osteoclast differentiation but not in cytokine production, phagocytosis, or dendritic cell differentiation of bone marrow macrophages, Endocrinology, 144, 4999, 10.1210/en.2003-0166 · DOI
- Shortman, 2007, Steady-state and inflammatory dendritic-cell development, Nat. Rev. Immunol., 7, 19, 10.1038/nri1996 · DOI · Paper page
- Geissmann, 2010, Development of monocytes, macrophages, and dendritic cells, Science, 327, 656, 10.1126/science.1178331 · DOI · Paper page
- Palucka, 2011, Recent developments in cancer vaccines, J. Immunol., 186, 1325, 10.4049/jimmunol.0902539 · DOI · Paper page
- Miyamoto, 2001, Bifurcation of osteoclasts and dendritic cells from common progenitors, Blood, 98, 2544, 10.1182/blood.V98.8.2544 · DOI · Paper page
- Feldman, 1997, STAT5A-deficient mice demonstrate a defect in granulocyte-macrophage colony-stimulating factor-induced proliferation and gene expression, Blood, 90, 1768, 10.1182/blood.V90.5.1768 · DOI · Paper page
- Cohen, 2008, STAT3- and STAT5-dependent pathways competitively regulate the pan-differentiation of CD34pos cells into tumor-competent dendritic cells, Blood, 112, 1832, 10.1182/blood-2007-12-130138 · DOI
- Slots, 2004, Systemic antibiotics in periodontics, J. Periodontol., 75, 1553, 10.1902/jop.2004.75.11.1553 · DOI · Paper page
- Rifkin, 1994, Modulation of bone resorption by tetracyclines, Ann. N. Y. Acad. Sci., 732, 165, 10.1111/j.1749-6632.1994.tb24733.x · DOI
- Zhang, 2007, Inhibiting wear particles-induced osteolysis with doxycycline, Acta Pharmacol. Sin., 28, 1603, 10.1111/j.1745-7254.2007.00638.x · DOI
- Bildt, 2007, CMT-3 inhibits orthodontic tooth displacement in the rat, Arch. Oral Biol., 52, 571, 10.1016/j.archoralbio.2006.11.009 · DOI
- Golub, 2010, Doxycycline effects on serum bone biomarkers in post-menopausal women, J. Dent. Res., 89, 644, 10.1177/0022034510363367 · doi:10.1177/0022034510363367
- Hanemaaijer, 1997, Matrix metalloproteinase-8 is expressed in rheumatoid synovial fibroblasts and endothelial cells. Regulation by tumor necrosis factor-alpha and doxycycline, J. Biol. Chem., 272, 31504, 10.1074/jbc.272.50.31504 · DOI · Paper page
- Foroodi, 2009, Interactions of doxycycline with chemotherapeutic agents in human breast adenocarcinoma MDA-MB-231 cells, Anticancer Drugs, 20, 115, 10.1097/CAD.0b013e32831c14ec · DOI
- Bettany, 2000, Tetracyclines induce apoptosis in osteoclasts, Bone, 27, 75, 10.1016/S8756-3282(00)00297-0 · DOI · Paper page
- Ramamurthy, 2002, Inhibition of matrix metalloproteinase-mediated periodontal bone loss in rats: a comparison of 6 chemically modified tetracyclines, J. Periodontol., 73, 726, 10.1902/jop.2002.73.7.726 · DOI
- Holmes, 2004, Chemically modified tetracyclines act through multiple mechanisms directly on osteoclast precursors, Bone, 35, 471, 10.1016/j.bone.2004.02.028 · doi:10.1016/j.bone.2004.02.028
- Nagasawa, 2011, Inhibitory effect of minocycline on osteoclastogenesis in mouse bone marrow cells, Arch. Oral Biol., 56, 924, 10.1016/j.archoralbio.2011.02.002 · DOI · Paper page
- Mizuno, 2002, Transgenic mice overexpressing soluble osteoclast differentiation factor (sODF) exhibit severe osteoporosis, J. Bone Miner. Metab., 20, 337, 10.1007/s007740200049 · DOI
- Vaira, 2008, RelA/p65 promotes osteoclast differentiation by blocking a RANKL-induced apoptotic JNK pathway in mice, J. Clin. Invest., 118, 2088
- Soysa, 2010, The pivotal role of the alternative NF-kappaB pathway in maintenance of basal bone homeostasis and osteoclastogenesis, J. Bone Miner. Res., 25, 809, 10.1359/jbmr.091030 · DOI
- Koide, 2009, Diphenylhydantoin inhibits osteoclast differentiation and function through suppression of NFATc1 signaling, J. Bone Miner. Res., 24, 1469, 10.1359/jbmr.090302 · DOI
- Takahashi, 1988, Osteoblastic cells are involved in osteoclast formation, Endocrinology, 123, 2600, 10.1210/endo-123-5-2600 · DOI · Paper page
- Takahashi, 2003, Generating murine osteoclasts from bone marrow, Methods Mol. Med., 80, 129
- Katagiri, 1994, Bone morphogenetic protein-2 converts the differentiation pathway of C2C12 myoblasts into the osteoblast lineage, J. Cell Biol., 127, 1755, 10.1083/jcb.127.6.1755 · DOI · Paper page
- Mizoguchi, 2009, Identification of cell cycle-arrested quiescent osteoclast precursors in vivo, J. Cell Biol., 184, 541, 10.1083/jcb.200806139 · DOI · Paper page
- Matsuo, 2004, Nuclear factor of activated T-cells (NFAT) rescues osteoclastogenesis in precursors lacking c-Fos, J. Biol. Chem., 279, 26475, 10.1074/jbc.M313973200 · DOI · Paper page
- Barry, 2007, Uniform sensitivity of FLT3 activation loop mutants to the tyrosine kinase inhibitor midostaurin, Blood, 110, 4476, 10.1182/blood-2007-07-101238 · doi:10.1182/blood-2007-07-101238
- Grigoriadis, 1994, c-Fos: a key regulator of osteoclast-macrophage lineage determination and bone remodeling, Science, 266, 443, 10.1126/science.7939685 · DOI · Paper page
- Williams, 1996, Minocycline prevents the decrease in bone mineral density and trabecular bone in ovariectomized aged rats, Bone, 19, 637, 10.1016/S8756-3282(96)00302-X · DOI
- Gomes, 2007, Effect of therapeutic levels of doxycycline and minocycline in the proliferation and differentiation of human bone marrow osteoblastic cells, Arch. Oral Biol., 52, 251, 10.1016/j.archoralbio.2006.10.005 · DOI
- Anderson, 1997, A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function, Nature, 390, 175, 10.1038/36593 · DOI · Paper page
- Wong, 1997, TRANCE (tumor necrosis factor [TNF]-related activation-induced cytokine), a new TNF family member predominantly expressed in T cells, is a dendritic cell-specific survival factor, J. Exp. Med., 186, 2075, 10.1084/jem.186.12.2075 · DOI · Paper page
- Ashcroft, 2003, Colonic dendritic cells, intestinal inflammation, and T cell-mediated bone destruction are modulated by recombinant osteoprotegerin, Immunity, 19, 849, 10.1016/S1074-7613(03)00326-1 · DOI · Paper page
- Zhu, 2002, Minocycline inhibits cytochrome c release and delays progression of amyotrophic lateral sclerosis in mice, Nature, 417, 74, 10.1038/417074a · DOI · Paper page
- Nikodemova, 2006, Minocycline exerts inhibitory effects on multiple mitogen-activated protein kinases and IkappaBalpha degradation in a stimulus-specific manner in microglia, J. Neurochem., 96, 314, 10.1111/j.1471-4159.2005.03520.x · DOI · Paper page
- Nikodemova, 2007, Minocycline down-regulates MHC II expression in microglia and macrophages through inhibition of IRF-1 and protein kinase C (PKC)alpha/betaII, J. Biol. Chem., 282, 15208, 10.1074/jbc.M611907200 · DOI · Paper page
- Cazalis, 2008, Doxycycline reduces lipopolysaccharide-induced inflammatory mediator secretion in macrophage and ex vivo human whole blood models, J. Periodontol., 79, 1762, 10.1902/jop.2008.080051 · doi:10.1902/jop.2008.080051
Cited by
Mascia, F., Lam, G., Keith, C., Garber, C., Steinberg, S. M., Kohn, E., & Yuspa, S. H. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3005773 · Cited by 105
Ma, Y., Song, J., Almassri, H. N. S., Zhang, D., Zhang, T., Cheng, Y., & Wu, X. (2020) · Drug Delivery · doi:10.1080/10717544.2019.1709921 · Cited by 51
Metadata
- Authors
- Kinugawa, S., Koide, M., Kobayashi, Y., Mizoguchi, T., Ninomiya, T., Muto, A., Kawahara, I., Nakamura, M., Yasuda, H., Takahashi, N., & Udagawa, N.
- Affiliations
- Graduate School of Oral Medicine, Matsumoto Dental University , Nagano 399-0781 ,
- Institute for Oral Science, Matsumoto Dental University , Nagano 399-0781 ,
- Department of Biochemistry, Matsumoto Dental University , Nagano 399-0781 ,
- Planning and Development Group, Bioindustry Division, Oriental Yeast Co., Ltd , Tokyo 174-8505 ,
- Venue
- The Journal of Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 2012-02
- Volume
- 188
- Issue
- 4
- Pages
- 1772-1781
- ISSN
- 0022-1767
- 1550-6606
- Cited by
- 32
- References
- 4
- Language
- en
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.